Biohaven Therapeutics Ltd. — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

3 Recruiting

5 Completed trials

18 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (Other)

Phase III: 3 Phase II/III: 3 Phase II: 2 Phase I (Other): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Spinal muscular atrophy 1

Top IMPs

BHV-7000 4 TRORILUZOLE 2 (2R,5S)-TETRAHYDRO-5-(2-METHYL-1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDIN-1-YL)-2H-PYRAN-2-ACETONITRILE 1 IOFLUPANE (123I) 1 TALDEFGROBEP ALFA 1

All trials

9 total

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Phase II/III 10 countries (2R,5S)-TETRAHYDRO-5-(2-METHYL-1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDIN-1-YL)-2H-PYRA…
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Phase II 18 countries BHV-7000
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508539-30-00 Phase II 9 countries BHV-7000
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508811-21-00 Phase II/III 11 countries BHV-7000
A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy. Ended

2024-511852-42-00 Phase III 7 countries TALDEFGROBEP ALFA
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN… Ended

2023-508812-45-00 Phase II/III 11 countries BHV-7000
A study to determine if BHV-2100 and BHV-7000 are effective, safe, and tolerable as a pain medication in healthy male participants Ended

2024-512187-57-00 Phase I (Other) 1 country
Long-term Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder Ended

2024-512108-20-00 Phase III 2 countries TRORILUZOLE
A research study investigating troriluzole as a possible treatment for Obsessive Compulsive Disorder Ended

2024-514585-39-00 Phase III 2 countries TRORILUZOLE

Showing 1–9 of 9 trials

← All sponsors A–Z